-- Surgery 2 Question Bank: Topic 35 - Breast Disorders (33 MCQs)
-- Category: Surgery 2 (a0000002-0000-0000-0000-000000000002)
-- Topic: Breast Disorders (c2000035-0000-0000-0000-000000000035)

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES
('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The breast receives its blood supply primarily from:', 'External carotid artery', 'Internal thoracic artery (internal mammary) and lateral thoracic artery', 'Subclavian artery directly', 'Brachial artery', 'Aorta directly', 'B', 'Breast blood supply: internal thoracic artery (perforators through intercostals), lateral thoracic artery, thoracoacromial artery. Venous drainage parallels arterial.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The primary lymphatic drainage of the breast is to:', 'Supraclavicular nodes', 'Axillary lymph nodes (75%)', 'Internal mammary nodes', 'Cervical nodes', 'Inguinal nodes', 'B', 'Lymphatic drainage: ~75% to axillary nodes, ~25% to internal mammary nodes (medial lesions). Levels I (lateral to pectoralis minor), II (behind), III (medial to).', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Fibroadenoma is characterized by:', 'Malignant transformation', 'Benign fibroepithelial tumor, mobile, well-circumscribed (breast mouse)', 'Irregular margins', 'Skin tethering', 'Axillary lymphadenopathy', 'B', 'Fibroadenoma: most common benign breast tumor in young women. Mobile, rubbery, well-defined. Does not increase cancer risk. May observe, excise if enlarging/symptomatic.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Triple assessment of a breast lump includes:', 'Only clinical examination', 'Clinical examination, imaging (mammogram/ultrasound), and tissue diagnosis (FNA/biopsy)', 'Blood tests only', 'CT scan', 'MRI only', 'B', 'Triple assessment: clinical exam, imaging (mammography >40y, ultrasound <40y or for cystic lesions), tissue diagnosis (FNA cytology or core biopsy histology). All three needed.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Breast cysts are best diagnosed and treated by:', 'Mammography alone', 'Ultrasound-guided aspiration', 'Open biopsy', 'MRI', 'Observation only', 'B', 'Simple cysts: ultrasound shows anechoic, well-circumscribed lesion. Aspiration diagnostic and therapeutic (non-bloody fluid, cyst disappears). Complex cysts need biopsy.', 'easy', 'application'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Fibrocystic change (fibrocystic disease) is characterized by:', 'Malignancy', 'Benign breast changes including cysts, fibrosis, and epithelial hyperplasia', 'Single dominant mass', 'Always requires surgery', 'Unilateral involvement', 'B', 'Fibrocystic changes: most common breast condition. Cyclical pain, nodularity, cysts. Varies with menstrual cycle. Most forms do not increase cancer risk. Conservative management.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Phyllodes tumor differs from fibroadenoma by:', 'Being always benign', 'Being larger, rapidly growing, with leaf-like projections on histology', 'Being always small', 'Never requiring surgery', 'Being inflammatory', 'B', 'Phyllodes tumor: fibroepithelial, similar to fibroadenoma but larger, faster growth. Benign, borderline, or malignant. Treatment: wide local excision with margins. Can recur.', 'medium', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Breast abscess is most commonly seen in:', 'Postmenopausal women', 'Lactating women (puerperal/lactational abscess)', 'Adolescents', 'Men', 'Children', 'B', 'Lactational abscess: during breastfeeding. Staph aureus most common. Treat: antibiotics, drainage (aspiration or incision). Continue breastfeeding. Periductal mastitis in smokers.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Treatment of breast abscess includes:', 'Antibiotics alone always', 'Antibiotics and drainage (aspiration or incision)', 'Mastectomy', 'Radiation', 'Observation', 'B', 'Breast abscess: antibiotics + drainage. Ultrasound-guided aspiration for small abscesses. Incision and drainage for large/multiloculated. Culture and sensitivity. Continue breastfeeding if lactational.', 'easy', 'application'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Risk factors for breast cancer include all EXCEPT:', 'Early menarche and late menopause', 'Family history of breast cancer', 'BRCA1/BRCA2 mutations', 'Multiparity and prolonged breastfeeding', 'Nulliparity', 'D', 'Risk factors: early menarche, late menopause, nulliparity, late first pregnancy, HRT, obesity, alcohol, family history, BRCA mutations. Multiparity and breastfeeding are protective.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'BRCA1 and BRCA2 mutations are associated with:', 'Decreased cancer risk', 'Significantly increased risk of breast and ovarian cancer', 'Only male breast cancer', 'Benign conditions only', 'No genetic significance', 'B', 'BRCA1/2: tumor suppressor genes. BRCA1: 60-70% lifetime breast cancer risk, 40% ovarian. BRCA2: 45-55% breast, 15-20% ovarian. Also prostate, pancreatic cancers.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'The most common histological type of breast cancer is:', 'Lobular carcinoma', 'Invasive ductal carcinoma (70-80%)', 'Medullary carcinoma', 'Mucinous carcinoma', 'Pagets disease', 'B', 'Invasive ductal carcinoma (IDC/NST): 70-80% of breast cancers. Invasive lobular: 10-15%. Special types: tubular, mucinous, medullary, papillary (better prognosis).', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Ductal carcinoma in situ (DCIS) is:', 'Invasive cancer', 'Non-invasive proliferation of malignant cells within ducts', 'Always becomes invasive', 'Does not require treatment', 'Metastatic disease', 'B', 'DCIS: pre-invasive, confined to ducts (no basement membrane invasion). 30-50% may progress to invasive cancer. Treatment: surgery Â± radiation Â± hormone therapy. Screen-detected.', 'medium', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Pagets disease of the nipple is:', 'A skin condition unrelated to breast', 'Intraepithelial adenocarcinoma of nipple associated with underlying DCIS or invasive cancer', 'An infection', 'Benign condition', 'Eczema of nipple', 'B', 'Pagets disease: eczema-like nipple changes (erythema, scaling, ulceration). Paget cells in epidermis. Almost always associated with underlying breast cancer. Biopsy and treat underlying disease.', 'medium', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Inflammatory breast cancer presents with:', 'Discrete mass only', 'Diffuse erythema, warmth, peau dorange, without discrete mass', 'Normal breast examination', 'Only nipple discharge', 'Bilateral involvement', 'B', 'Inflammatory breast cancer: aggressive, dermal lymphatic invasion. Peau dorange (skin edema), erythema, warmth, diffuse breast enlargement. Often no discrete mass. Poor prognosis.', 'medium', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Peau dorange in breast cancer indicates:', 'Early disease', 'Skin lymphatic obstruction by tumor', 'Infection', 'Benign condition', 'Fibroadenoma', 'B', 'Peau dorange (orange peel skin): dermal edema from lymphatic obstruction by tumor. Hair follicles tethered, surrounding edema creates dimpled appearance. Advanced local disease.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Hormone receptor status in breast cancer refers to:', 'Blood hormone levels', 'Estrogen receptor (ER) and progesterone receptor (PR) expression by tumor', 'Patient hormone levels', 'Thyroid status', 'Adrenal function', 'B', 'ER/PR status: ER+ and/or PR+ tumors (~70%) respond to endocrine therapy (tamoxifen, aromatase inhibitors). Better prognosis than ER- tumors.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'HER2-positive breast cancer is characterized by:', 'Better prognosis without treatment', 'Overexpression of HER2/neu receptor, responds to trastuzumab (Herceptin)', 'Low grade', 'Does not need targeted therapy', 'Hormone receptor positive always', 'B', 'HER2+ (15-20%): amplified HER2/neu gene. More aggressive. Responds to anti-HER2 therapy (trastuzumab, pertuzumab). IHC 3+ or FISH amplified. Dramatically improved prognosis with targeted therapy.', 'medium', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Triple-negative breast cancer is:', 'ER+, PR+, HER2+', 'ER-, PR-, HER2-negative', 'ER+ only', 'HER2+ only', 'Always benign', 'B', 'Triple-negative: ER-, PR-, HER2-. 15% of breast cancers. More aggressive, limited targeted options. Chemotherapy mainstay. Often BRCA-associated. Research into immunotherapy ongoing.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Breast-conserving surgery (lumpectomy) with radiation is equivalent to mastectomy for:', 'All breast cancers', 'Early-stage breast cancer with clear margins', 'Inflammatory breast cancer', 'Multicentric disease', 'Large tumor-to-breast ratio', 'B', 'Breast conservation: equivalent survival to mastectomy for early-stage cancer (T1-T2, unifocal). Requires negative margins, ability to achieve acceptable cosmesis, access to radiation.', 'medium', 'application'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Contraindications to breast-conserving surgery include:', 'Small tumor', 'Multicentric disease, prior chest wall radiation, inability to achieve clear margins', 'Unifocal disease', 'Patient preference for conservation', 'Stage I disease', 'B', 'BCS contraindications: multicentric cancer, prior breast/chest radiation, positive margins after re-excision, large tumor-to-breast ratio, inflammatory cancer, pregnancy (relative).', 'medium', 'application'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Sentinel lymph node biopsy (SLNB) is indicated for:', 'All breast cancer patients', 'Clinically node-negative invasive breast cancer to stage the axilla', 'Known axillary metastases', 'Inflammatory breast cancer', 'After axillary radiation', 'B', 'SLNB: identifies first draining node(s). If negative, avoids axillary dissection (reduces lymphedema). If positive, may proceed to ALND or sometimes omit (ACOSOG Z0011 criteria).', 'medium', 'application'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Axillary lymph node dissection (ALND) is indicated when:', 'Never needed', 'Positive sentinel nodes (with exceptions), clinically positive axilla, or inflammatory cancer', 'All breast cancers', 'Negative sentinel node', 'DCIS only', 'B', 'ALND: positive axilla, certain SLN+ scenarios. Z0011: 1-2 positive SLN with BCS + whole breast RT may omit ALND. Reduces staging but increases lymphedema risk.', 'medium', 'application'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Adjuvant radiation therapy after breast conservation:', 'Is optional', 'Is standard to reduce local recurrence', 'Increases mortality', 'Only for high-grade tumors', 'Replaces surgery', 'B', 'Radiation after BCS: whole breast radiation standard (reduces local recurrence from 30-40% to 5-10%). Boost to tumor bed. Partial breast irradiation for select low-risk cases.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Tamoxifen is:', 'An aromatase inhibitor', 'A selective estrogen receptor modulator (SERM) for ER+ breast cancer', 'A HER2-targeted therapy', 'Chemotherapy', 'A bisphosphonate', 'B', 'Tamoxifen: SERM, blocks estrogen receptor in breast. Used in premenopausal and postmenopausal ER+ cancer. 5-10 years adjuvant therapy. Side effects: hot flashes, VTE, endometrial cancer.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Aromatase inhibitors (anastrozole, letrozole, exemestane) are used in:', 'Premenopausal women', 'Postmenopausal women with ER+ breast cancer', 'Triple-negative cancer', 'HER2+ cancer only', 'All breast cancers', 'B', 'Aromatase inhibitors: block peripheral estrogen synthesis. Only effective in postmenopausal women (ovaries not producing estrogen). Superior to tamoxifen in postmenopausal.', 'medium', 'application'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Neoadjuvant chemotherapy for breast cancer is used to:', 'Replace surgery', 'Downstage tumors to allow breast conservation and assess tumor response', 'Only for metastatic disease', 'Avoid radiation', 'Treat benign disease', 'B', 'Neoadjuvant therapy: before surgery. Goals: downstage tumor (enable BCS), treat micrometastases, assess response (pathologic complete response prognostic). Standard for locally advanced/inflammatory.', 'medium', 'application'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Gynecomastia is defined as:', 'Male breast cancer', 'Benign enlargement of male breast glandular tissue', 'Female breast hypertrophy', 'Accessory breast tissue', 'Breast infection in males', 'B', 'Gynecomastia: benign proliferation of male breast glandular tissue. Causes: physiologic (puberty, elderly), drugs (spironolactone, marijuana, steroids), hormonal, systemic disease.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Medications that can cause gynecomastia include:', 'Antibiotics only', 'Spironolactone, cimetidine, estrogens, and marijuana', 'Only chemotherapy', 'NSAIDs', 'ACE inhibitors', 'B', 'Drug-induced gynecomastia: spironolactone, cimetidine, ketoconazole, estrogens, anabolic steroids, marijuana, alcohol, digoxin, anti-androgens.', 'medium', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Male breast cancer is:', 'Very common', 'Rare (<1% of breast cancers) but often presents at later stage', 'Never occurs', 'Always benign', 'Only in elderly', 'B', 'Male breast cancer: <1% of breast cancers, 1% of male cancers. Often ER+. Presents later stage (no screening). Treatment similar to female. Risk factors: BRCA2, Klinefelter syndrome.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Bloody nipple discharge is concerning for:', 'Fibroadenoma', 'Intraductal papilloma or carcinoma', 'Fibrocystic change', 'Fat necrosis', 'Mastitis', 'B', 'Bloody/serosanguinous discharge: intraductal papilloma (most common), DCIS, invasive cancer. Single duct, spontaneous. Requires imaging and ductogram/ductoscopy/excision.', 'easy', 'knowledge'),

('c2000035-0000-0000-0000-000000000035'::uuid, 'a0000002-0000-0000-0000-000000000002'::uuid, 'Mammographic screening is generally recommended starting at age:', '30 years', '40-50 years depending on guidelines', '60 years', 'Any age', 'Only for high-risk', 'B', 'Screening mammography: guidelines vary. Generally start at 40-50, annual or biennial until 74+. High-risk may start earlier with MRI. Reduces breast cancer mortality.', 'easy', 'knowledge');
